Medication 3: COMT Inhibitors: Enhancing Levodopa Effectiveness
Catechol-O-methyltransferase (COMT) inhibitors are a class of medications designed to enhance the effectiveness of levodopa. By inhibiting the COMT enzyme, these drugs help prolong the effects of levodopa, leading to more stable dopamine levels in the brain. Examples of COMT inhibitors include entacapone (Comtan) and tolcapone (Tasmar).
COMT inhibitors are often prescribed in combination with levodopa and carbidopa for patients who experience fluctuations in symptom control or “wearing-off” periods. These medications can help extend the duration of levodopa’s benefits, providing more consistent relief from Parkinson’s symptoms.
Although COMT inhibitors can significantly improve the effectiveness of levodopa, they also have potential side effects. Some patients may experience diarrhea, nausea, and increased risk of dyskinesia. As with other Parkinson’s medications, healthcare providers will closely monitor patients and adjust their treatment plans to minimize side effects and maximize benefits. (3)
